ReviewExpert review of vaccines2017
Advances and challenges: dendritic cell vaccination strategies for glioblastoma.
Review in Expert review of vaccines, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Delayed Effect of Dendritic Cells Vaccination on Survival in Glioblastoma: A Systematic Review and Meta-Analysis.Current oncology (Toronto, Ont.) · 2022Pooled it
- Article
- rWTC-MBTA Vaccine Induces Potent Adaptive Immune Responses Against Glioblastomas via Dynamic Activation of Dendritic Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Trial watch: anticancer vaccination with dendritic cells.Oncoimmunology · 2024Review
- The Expression Pattern and Clinical Significance of Lysyl Oxidase Family in Gliomas.Doklady. Biochemistry and biophysics · 2023Article
- Challenges in glioblastoma immunotherapy: mechanisms of resistance and therapeutic approaches to overcome them.British journal of cancer · 2022Review
- Review
- Friends with Benefits: Chemokines, Glioblastoma-Associated Microglia/Macrophages, and Tumor Microenvironment.International journal of molecular sciences · 2022Review
- Pediatric versus adult high grade glioma: Immunotherapeutic and genomic considerations.Frontiers in immunology · 2022Review
- Trial watch: Dendritic cell (DC)-based immunotherapy for cancer.Oncoimmunology · 2022Article
- Advanced MRI Protocols to Discriminate Glioma From Treatment Effects: State of the Art and Future Directions.Frontiers in radiology · 2022Review
- Advanced Magnetic Resonance Imaging in Pediatric Glioblastomas.Frontiers in neurology · 2021Review
- DCs-based therapies: potential strategies in severe SARS-CoV-2 infection.International journal of medical sciences · 2021Review
- Improved prognostication of glioblastoma beyond molecular subtyping by transcriptional profiling of the tumor microenvironment.Molecular oncology · 2020Article
- First in human dose calculation of a single-chain bispecific antibody targeting glioma using the MABEL approach.Journal for immunotherapy of cancer · 2020Article
- Extracorporeal Photochemotherapy: Mechanistic Insights Driving Recent Advances and Future Directions.The Yale journal of biology and medicine · 2020Review
- Immunotherapy for pediatric brain tumors: past and present.Neuro-oncology · 2019Review
- Current State of Immunotherapy for Treatment of Glioblastoma.Current treatment options in oncology · 2019Review
- Glioblastoma: Microenvironment and Niche Concept.Cancers · 2018Review
- miR-370-3p Is a Therapeutic Tool in Anti-glioblastoma Therapy but Is Not an Intratumoral or Cell-free Circulating Biomarker.Molecular therapy. Nucleic acids · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
introductionGlioblastoma is the most common primary brain tumor in adults and prognosis remains poor with a median survival of approximately 15-17 months. This review provides an overview of recent advances in the field of glioblastoma immunotherapy. Areas covered: Recent advances in dendritic cell vaccination immunotherapy are showing encouraging results in clinical trials and promise to extend patient survival. In this report we discuss current scientific knowledge regarding dendritic cell (DC) vaccines, including approaches to differentiating, priming, and injecting dendritic cells to achieve maximal anti-tumor efficacy in glioblastoma. These findings are compared to recently completed and currently ongoing glioblastoma clinical trials. Novel methods such as 'fastDCs' and vaccines targeting DCs in-vivo may offer more effective treatment when compared to traditional DC vaccines and have already entered the clinic. Expert commentary: Finally, we discuss the challenges of T-cell dysfunctions caused by glioblastoma immunosuppression and how they affect dendritic cell vaccinations approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.